Lot A Devriese Selected Research

Breast Neoplasms (Breast Cancer)

2/2013

Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lot A Devriese Research Topics

Disease

11	Neoplasms (Cancer) 12/2023 - 08/2012
10	Squamous Cell Carcinoma of Head and Neck 01/2023 - 01/2019
9	Head and Neck Neoplasms (Head and Neck Cancer) 01/2024 - 01/2020
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 04/2024 - 01/2021
2	Nausea 01/2022 - 01/2020
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
2	Prostatic Neoplasms (Prostate Cancer) 12/2021 - 01/2021
2	Circulating Neoplastic Cells 08/2012 - 12/2011
1	Vomiting 04/2024
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 04/2024
1	Syncope (Fainting) 04/2024
1	Pneumonia (Pneumonitis) 04/2024
1	Carcinoma (Carcinomatosis) 03/2023
1	Weight Loss (Weight Reduction) 10/2022
1	Oropharyngeal Neoplasms 10/2022
1	Thrombocytopenia (Thrombopenia) 01/2022
1	Fatigue 01/2022
1	Esophagitis 01/2022
1	Leukopenia 01/2022
1	Neutropenia 01/2022
1	Disease Progression 12/2021
1	Salivary Gland Neoplasms (Salivary Gland Cancer) 12/2021
1	Infections 01/2021
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2021
1	Basal Cell Nevus Syndrome (Gorlin Syndrome) 01/2021
1	multiple Basal cell carcinoma 01/2021
1	Merkel Cell Carcinoma 01/2020
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2020
1	Exanthema (Rash) 01/2020
1	Breast Neoplasms (Breast Cancer) 02/2013

Drug/Important Bio-Agent (IBA)

5	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 01/2022
4	Biomarkers (Surrogate Marker)IBA 12/2023 - 12/2011
3	NivolumabIBA 04/2024 - 01/2020
3	LigandsIBA 01/2022 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2023 - 08/2012
2	PlatinumIBA 10/2022 - 01/2022
1	IpilimumabIBA 04/2024
1	TransferasesIBA 04/2024
1	Lipase (Acid Lipase)FDA Link 04/2024
1	cemiplimabIBA 04/2024
1	Adenosine Triphosphate (ATP)IBA 03/2023
1	Protein Kinase InhibitorsIBA 03/2023
1	CopperIBA 03/2023
1	NucleosidesIBA 03/2023
1	Alanine Transaminase (SGPT)IBA 01/2022
1	Cytostatic AgentsIBA 01/2022
1	Death Domain ReceptorsIBA 01/2022
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	AntigensIBA 12/2021
1	Proteins (Proteins, Gene)FDA Link 12/2021
1	177Lu-PSMA-617IBA 12/2021
1	Circulating Tumor DNAIBA 12/2021
1	Cell-Free Nucleic AcidsIBA 12/2021
1	Docetaxel (Taxotere)FDA Link 01/2021
1	CarcinogensIBA 01/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	HhAntag691IBA 01/2021
1	Ritonavir (Norvir)FDA Link 01/2021
1	mirdametinibIBA 01/2020
1	dacomitinibIBA 01/2020
1	taxaneIBA 02/2013
1	eribulin FDA Link 02/2013
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 08/2012
1	Epidermal Growth Factor (EGF)IBA 08/2012

Therapy/Procedure

6	Therapeutics 04/2024 - 01/2017
6	Chemoradiotherapy 01/2023 - 01/2020
4	Drug Therapy (Chemotherapy) 03/2023 - 01/2022
2	Radiotherapy 10/2022 - 12/2021
2	Enteral Nutrition (Feeding, Tube) 01/2022 - 01/2020
1	Time-to-Treatment 01/2024
1	Brachytherapy 03/2023
1	Immunotherapy 01/2021
1	Castration 01/2021
1	Neoadjuvant Therapy 01/2021
1	Gastrostomy 01/2020